BNC105-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEBNC105Cat. No.: HY-16114CAS No.: 945771-74-4分式: CHO分量: 372.37作靶點: Microtubule/Tubulin作通路: Cell Cycle/DNA Damage; Cytoskeleton儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 25 mg/mL (67.14

2、mM; Need ultrasonic)H2O : 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (6.71 mM); Suspended solution; Need ultrasonic and warming2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (6.71 mM); Suspended solution; Need ultrasonic and warming3. 請依序添加每種溶劑： 10% DMSO 90% corn

3、oil1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemESolubility: 2.5 mg/mL (6.71 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 BNC105種具有抗增殖和破壞腫瘤管功能的，微管蛋聚合抑制劑。IC50 & Target BNC105 exhibited excellent potency against a panel of different cancer cell lines with IC50 1 nM for DU145,Calu-6, MDA-MB-231 etc. Th

4、e selectivity observed for BNC105 against activated over quiescent HUVECswas also observed in human aortic arterial endothelial cells (HAAECs). BNC105 also exhibited good potencytoward the cisplatin resistant cell line A2780cis.REFERENCES1. Flynn BL, et al. Discovery of 7-hydroxy-6-methoxy-2-methyl-

5、3-(3,4,5-trimethoxybenzoyl)benzobfuran (BNC105), a tubulinpolymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. J Med Chem. 2011 Sep 8;54(17):6014-27.2. Kremmidiotis G, et al. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor

6、vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther. 2010 Jun;9(6):1562-73.3. Inglis DJ, et al. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther. 2014;15(11):1552-60.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400